Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HCP1904 in Healthy Subjects
NCT05191563Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HCP1904-2 in hypertension (HTN) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Losartan at Day 15, Area Under the Curve to the Last Measurable Concentration (AUClast) of Losartan at Day 15 and 4 more. Started Jul 2021; status: completed.
02
Drugs
HCP1904-2
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05191563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191563.